Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience

BackgroundRipretinib was recently approved for the fourth-line targeted therapy for advanced gastrointestinal stromal tumor (GIST) refractory to imatinib, sunitinib, and regorafenib based on the pivotal INVICTUS phase III study. The INVICTUS study demonstrated significantly improved median progressi...

Full description

Bibliographic Details
Main Authors: Li-Ching Lin, Wen-Kuan Huang, Chueh-Chuan Yen, Ching-Yao Yang, Meng-Ta Sung, Natalie S. M. Wong, Daniel T. T. Chua, Sarah W. M. Lee, Jen-Shi Chen, Chun-Nan Yeh
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
ripretinib
GIST
compassionate use
advanced
metastatic
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.883399/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.883399/full

Similar Items